Breast Cancer

FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer

Breast Cancer, FDA Approvals, News & Updates, In the News

On April 4, 2019, the US Food and Drug Administration (FDA) expanded the indication of palbociclib (Ibrance; Pfizer), a kinase inhibitor, in combination with specific endocrine therapies for men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This is the first hormonal-based therapy to be approved for men. [ Read More ]

T-DM1 Reduces Residual Invasive Disease in Patients with HER2-Positive Breast Cancer After Chemotherapy

Phoebe Starr

March 2019, Vol 9, No 3 - Breast Cancer

The adjuvant use of the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1; Kadcyla) led to a clinically meaningful and statistically significant improvement in invasive disease-free survival (ie, survival free of invasive disease or death) compared with trastuzumab (Herceptin) in patients with HER2-­positive early-stage breast cancer and residual invasive disease, despite the use of neoadjuvant chemotherapy plus HER2-­targeted therapy, according to the preliminary results of the phase 3 KATHERINE trial. These findings were reported at the 2018 San Antonio Breast Cancer Symposium. [ Read More ]

Atezolizumab/Nab-Paclitaxel of No Benefit in PD-L1–Negative Triple-Negative Breast Cancer

Phoebe Starr

March 2019, Vol 9, No 3 - Breast Cancer

Triple-negative breast cancer (TNBC) is considered one of the most difficult breast cancers to treat, with few therapeutic options. In an overall analysis of the phase 3 IMpassion130 trial, investigators showed that using the checkpoint inhibitor atezolizumab (Tecentriq), a PD-L1 inhibitor, with nab-paclitaxel (Abraxane) chemotherapy improved disease-free survival (DFS) and overall survival (OS) in patients with advanced or metastatic TNBC compared with placebo plus nab-paclitaxel. [ Read More ]

Pathologic Complete Response to Neoadjuvant Chemotherapy May Guide Escalation and De-escalation Treatment Strategies in Localized Breast Cancer

Phoebe Starr

February 2019, Vol 9, No 2 - Breast Cancer

Achieving pathologic complete response (pCR) after neoadjuvant chemotherapy correlates with significantly improved event-free survival (EFS) and overall survival (OS) in patients with localized breast cancer, according to the results of a large comprehensive meta-analysis presented at the 2018 San Antonio Breast Cancer Symposium. [ Read More ]

Supervised Exercise During Chemotherapy Improves Cardiovascular Function in Women with Breast Cancer

Phoebe Starr

February 2019, Vol 9, No 2 - Breast Cancer

A 12-month supervised exercise program improved cardiovascular function in women receiving adjuvant chemotherapy for breast cancer, including anthracyclines and taxanes. By contrast, cardiovascular function decreased among women with breast cancer who did not exercise according to the program guidelines. These results of a randomized clinical trial were presented at the 2018 San Antonio Breast Cancer Symposium. [ Read More ]

5-mg Tamoxifen as Effective as 20 mg Daily in Early Localized Breast Cancer

Phoebe Starr

January 2019, Vol 9, No 1 - Breast Cancer

The large, randomized TAM-01 clinical trial demonstrated that 5 mg daily of tamoxifen for 3 years halved the risk for recurrence of breast intraepithelial neoplasia—atypical ductal hyperplasia, ductal carcinoma in situ (DCIS), and lobular carcinoma in situ—in women after surgery and reduced the risk for new contralateral breast cancer by 75% compared with placebo. [ Read More ]

Talzenna Approved for HER2-Negative, Locally Advanced Breast Cancer with Germline BRCA Mutations

December 2018, Vol 8, No 12 - Breast Cancer, FDA Approvals, News & Updates

On October 16, 2018, the FDA approved talazoparib (Talzenna; Pfizer), a poly (ADP-ribose) polymerase (PARP) inhibitor, for the treatment of patients with HER2-­negative, locally advanced or metastatic breast cancer and deleterious or suspected deleterious germline BRCA mutation, as identified by an FDA-approved test. [ Read More ]